arrow
Z

Zachary L. Skidmore

university of missouri columbia
H指数:28
被引数:4,302

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Whole Exome Sequencing of Feline Oral Squamous Cell Carcinoma Reveals Genomic Parallels With Human Head and Neck Squamous Cell Carcinoma

猫口腔鳞状细胞癌的全外显子测序揭示其基因组与人类头颈鳞状细胞癌的平行性

2026-02-010
PRE
Combining cell-free DNA fragmentomes and total tumour volume improves prognostication and tumour response evaluation in patients with colorectal cancer liver metastases

结合细胞外DNA片段组和肿瘤总体积可改善结直肠癌肝转移患者的预后预测和肿瘤反应评估

2025-12-160
OAAI
Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer

细胞自由DNA的全基因组分析用于胰腺癌患者的治疗监测

2025-05-230
PRE
Hyperprogressive disease following bintrafusp alfa and DNA damaging chemotherapy in relapsed small cell lung cancer
2024-04-050
PRE
Monitoring response to immunotherapy using cell free DNA fragmentomes
2024-03-220
PRE
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
2023-09-159
OAAI
Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer
2023-03-2227
OAAI
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
2023-01-2410
OAAI
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase
2022-11-1410
OAAI
A community approach to the cancer-variant-interpretation bottleneck
2022-05-274
OA
Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis
2021-10-0536
OAAI
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer
2021-06-2624
OAAI
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial (vol 26, pg 5140, 2020)
2021-01-048
OA
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
2020-10-01225
OAAI